Keyphrases
Adverse Drug Reaction
100%
Off-label Use
38%
Spontaneous Reporting
32%
Hospital Physicians
27%
Pharmacovigilance
25%
Patient Register
21%
Rituximab
21%
Neurotoxic Effects
19%
Ertapenem
19%
Acute Confusional State
19%
Educational Session
19%
Outpatient Treatment
19%
Multicentric
19%
Severe Disease
19%
Hospital Outpatient Clinics
19%
Disease Activity
19%
Systemic Lupus Erythematosus
19%
Extrarenal
19%
Spain
19%
Spontaneous Adverse Drug Reaction Reporting
19%
Series Analysis
19%
Pediatric Hematology
19%
Creatinine Clearance
14%
Partial Response
10%
Complete Response
10%
Thrombocytopenia
10%
Management Agreements
10%
Neurotoxicity
9%
Educational Activities
9%
Pharmacovigilance System
8%
Teaching Hospital
8%
Clinical Evidence
8%
Pediatric Patients
8%
Feedback Sessions
7%
Physician Opinion
7%
Medical Specialities
7%
New Drugs
6%
Patient Characteristics
6%
Healthcare Management
6%
Treatment Record
6%
LDL-C Reduction
6%
Adverse Effects
5%
Clinical Response
5%
Cutaneous Lupus Erythematosus
5%
Neurological Manifestations
5%
SLE Disease Activity Index (SLEDAI)
5%
Joint Involvement
5%
Preventability
5%
High Variability
5%
Clinical Characteristics
5%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Drug Reaction
100%
Retrospective Study
44%
Off-Label Use
38%
Pharmacovigilance
36%
Rituximab
25%
Systemic Lupus Erythematosus
19%
Disease Activity
19%
Ertapenem
19%
Prospective Study
19%
Disease
19%
Confusion
19%
Hypercholesterolemia
19%
Proprotein Convertase 9
19%
Alirocumab
19%
Evolocumab
19%
Cardiovascular Risk
19%
Adverse Event
15%
Creatinine
14%
Clinical Trial
12%
Thrombocytopenia
10%
Neurotoxicity
9%
Prospective Cohort Study
6%
Omalizumab
6%
Clostridium Botulinum Type A
6%
Familial Hypercholesterolemia
6%
Cardiovascular Disease
6%
Remission
5%
